Haemonetics (NYSE:HAE - Get Free Report) had its target price lifted by equities researchers at Citizens Jmp from $115.00 to $144.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a "market outperform" rating on the medical instruments supplier's stock. Citizens Jmp's target price would suggest a potential upside of 16.92% from the company's current price.
Several other equities analysts have also weighed in on the stock. Weiss Ratings restated a "hold (c)" rating on shares of Haemonetics in a research report on Wednesday, November 4th. Citigroup boosted their target price on shares of Haemonetics from $123.00 to $149.00 and gave the stock a "buy" rating in a report on Friday, November 6th. Robert W. Baird increased their target price on shares of Haemonetics from $96.00 to $119.00 and gave the company an "outperform" rating in a research note on Friday, August 21st. Jefferies Financial Group initiated coverage on shares of Haemonetics in a report on Friday. They set a "buy" rating and a $150.00 target price for the company. Finally, Barrington Research lifted their price target on shares of Haemonetics from $140.00 to $145.00 and gave the stock an "outperform" rating in a research report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $130.50.
Read Our Latest Stock Analysis on Haemonetics
Haemonetics Trading Up 0.2%
Shares of Haemonetics stock opened at $123.16 on Monday. The company has a quick ratio of 1.83, a current ratio of 2.84 and a debt-to-equity ratio of 1.24. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of 55.23, a price-to-earnings-growth ratio of 2.46 and a beta of 0.62. The business has a fifty day simple moving average of $113.34 and a 200-day simple moving average of $81.36. Haemonetics has a fifty-two week low of $51.00 and a fifty-two week high of $132.00.
Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.06. The business had revenue of $357.76 million during the quarter, compared to analysts' expectations of $345.15 million. Haemonetics had a return on equity of 27.42% and a net margin of 7.52%. The company's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.27 earnings per share. On average, equities analysts forecast that Haemonetics will post 5.32 EPS for the current fiscal year.
Insider Activity at Haemonetics
In other news, CAO Farris Maryanne Maunsell sold 836 shares of the business's stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total transaction of $101,147.64. Following the sale, the chief accounting officer owned 5,828 shares in the company, valued at $705,129.72. The trade was a 12.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.07% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Haemonetics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. Bank of America Corp DE purchased a new stake in Haemonetics in the 2nd quarter worth approximately $33,326,000. Assenagon Asset Management S.A. boosted its stake in shares of Haemonetics by 1,191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier's stock valued at $47,762,000 after buying an additional 418,470 shares during the period. William Blair Investment Management LLC acquired a new stake in shares of Haemonetics during the 2nd quarter valued at $24,906,000. Bank of New York Mellon Corp acquired a new stake in shares of Haemonetics during the 2nd quarter valued at $21,566,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier's stock valued at $74,731,000 after acquiring an additional 233,119 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.